Merck announces leadership changes; president of GHH to step down

By Emily Bader
Kenilworth | Dec 11, 2018 at 10:25 am

Merck announced Tuesday its president of global human health, Adam H. Schechter, will be stepping down from his role and into an advisory capacity to the CEO, effective Dec. 31.

The company said the change is due to it reshaping its commercial organization and has plans to create two new executive committee roles.

Frank Clyburn has been named chief commercial officer and Michael Nally has been named to chief marketing officer, both will serve on the executive committee.

Schechter served as president of GHH since 2010 and joined Merck in 1988.

“It has been my honor to be a part of Merck for 30 years and to lead Global Human Health since 2010,” Schechter said. “I am proud of how we have transformed our business and have been able to ensure that Merck’s remarkable medicines and vaccines are available to so many people around the world. I know that Frank and Mike share that passion for achieving Merck’s mission, and I am confident that they will build on GHH’s track record of driving growth and continue the momentum we have across our global business today.”

Clyburn previously served as president of the global oncology business at Merck. He joined the company in 2008. He will be responsible for operations and P&L across Merck’s human health commercial portfolio.

Nally most recently led Merck’s vaccines business. He will be responsible for global marketing and franchise strategies. Nally has been with Merck since 2003.

“Adam’s leadership and unwavering dedication to finding new ways to bring Merck’s medicines and vaccines to more patients around the world have been hallmarks of his time at Merck. I have relied on his experience and expertise as we evolved a world-class commercial organization, spanning primary care, hospital and specialty, vaccines and oncology,” Kenneth C. Frazier, chairman and CEO, Merck, said. “Because of him we are better positioned to address future opportunities and challenges as a global biopharmaceutical company, and Frank and Mike have a great foundation upon which to build future success.”

Emily Bader | ebader@roi-nj.com | emilybader